Current Size: 100%


New paper out on JAK2/STAT5 signaling as therapeutic target

The JAK2/STAT5 pathway is a novel potential target of therapy in canine mastocytoma, which is a frequently diagnosed cutaneous neoplasms in dogs. In non-resectable mastocytoma patients, novel targeted drugs are often applied. The transcription factor STAT5 has been implicated in the survival of human neoplastic mast cells. We have now reported the JAK2/STAT5 pathway as a novel target in canine mastocytoma.

New paper out on prognostic marker DCLK1 in head and neck cancer

New paper out on expression of DCLK1 in 127 patients being associated with poor survival. In particular, DCLK1 expression had a significant impact on survival of oropharyngeal carcinoma patients. Specifically, DCLK1+/HPV- patients had the worst prognosis after simultaneous assessment of DCLK1 and HPV status in comparison to the other three possible DCLK1/HPV constellations. Higher levels of DCLK1 mRNA were also associated with poor clinical outcome. Inhibition of DCLK1 in our HNSCC cell lines led to growth arrest and induction of apoptosis.

Metabolism drives growth and division of cancer cells

 The metabolic status of the cell and its supply of nutrients is signaled, amongst other, by the O-linked N-acetylglucosamine (GlcNAc) transferase (OGT). This enzyme links GlcNAc (orange squares) as a mark to STAT5 at the OH groups of threonine 92 (T). Cytokine receptors activate the kinase JAK2, which phosphorylates STAT5 on tyrosine 694 (Y) (red circles).

The metabolic state of tumor cells contributes to signals that control the proliferation of tumor cells. Already the German biochemist and Nobel Prize laureate Otto H. Warburg observed in the 1920s that tumor cells radically change their metabolism. This process was termed "Warburg Effect", however neglected until recently by cancer research, but the latest results show it is indeed of fundamental importance for the development of aggressive tumors.

Researchers of LBI-CR raised a record breaking 1.8 Mio € of external funds in 2016

In 2016 keyresearchers of the LBI-CR succeeded in raising more funds for their research than ever before. We are proud to report an outstanding success rate of 60%, as of ten proposals we received funding for six projects totalling an overall volume of € 1.8 Mio. With the renewal of one SFB and the intitiation of a new one Richard Moriggl maintains outstanding financial support by the Austrian Science Fund (FWF).

Luisa Schmidt receives Best Abstract Award at LBG Health Sciences Meeting

For the third time the LBG Health Sciences Meeting awarded the best research contributions with a prize. In the category "Cancer Research" Luisa Schmidt of the research group Florian Grebien at the LBI-CR was selected with her research on "Acute Myeloide Leukemia with CEBPA Mutations is sensitive against Blockade of Menin-MLL Interaction". We congratulate Luisa to this fine success.

Quest for origin of Ewing Sarcoma successful

The left image shows the anlage of a leg with EWS / FLI1 expression in which bone should already be formed. But the stem cells fail to produce precursor cells that support a healthy bone structure (arrows, compare to image right). Copyright: Unrestricted unmodified use with reference to the copyright holder Ludwig Boltzmann Gesellschaft

In order to develop better therapies against cancer, researchers are now faced with ever-increasing efforts. Since cancer is a complex disease affecting the entire organism, genetically modified mice play an important role in cancer research. Above all in rare cancers, clinically relevant animal models are essential to investigate the effect of new drugs. For this reason, researchers have tried for many years but failed to develop a suitable model for Ewing sarcoma.